3 unknown. 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Unknown 2 |
| Phase 3 | 1 | Unknown 1 |
Follow GNT Pharma: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Rescues On Reperfusion Damage In Cerebral Infarction by Nelonemdaz Neu2000KWL group, Placebo group - Ischemic Stroke | Phase 3 | Unknown | GNT Pharma | 496 | 2021-12-25 | 2022-09-26 |
| Antioxidant and NMDA Receptor Blocker Wins Anoxic Brain Damage of KorEa OHCA Patients Neu2000KWL High-dose group, Neu2000KWL Low-dose group, Placebo - Cardiac Arrest | Phase 2 | Unknown | GNT Pharma | 150 | 2018-11-29 | 2019-03-06 |
| Safety and Optimal Neuroprotection of neu2000 in Ischemic Stroke With Endovascular reCanalizion (SONIC) Neu2000KWL High-does group, Neu2000KWL Low-does group, Placebo - Ischemic Stroke | Phase 2 | Unknown | GNT Pharma | 210 | 2016-07-01 | 2017-07-13 |
Ischemic Stroke (2) · Heart Arrest (1) · Out-of-Hospital Cardiac Arrest (1)
South Korea (3)
Ji Man Hong, MD, PhD (1) · Jin-Ho Choi, MD (1) · Sun Uck Kwon, MD, PhD (1)
PMID 30005644, PMID 35871083, PMID 36065810, PMID 36746385, PMID 39874036, PMID 39899673